>
Switch to:

Altamira Therapeutics EV-to-EBITDA

: -1.26 (As of Today)
View and export this data going back to 2014. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Altamira Therapeutics's enterprise value is $11.43 Mil. Altamira Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was $-9.08 Mil. Therefore, Altamira Therapeutics's EV-to-EBITDA for today is -1.26.

The historical rank and industry rank for Altamira Therapeutics's EV-to-EBITDA or its related term are showing as below:

NAS:CYTO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.58   Med: -0.72   Max: 0.21
Current: -0.87

-1.58
0.21

During the past 10 years, the highest EV-to-EBITDA of Altamira Therapeutics was 0.21. The lowest was -1.58. And the median was -0.72.

NAS:CYTO's EV-to-EBITDA is ranked lower than
99.99% of the 37 Companies
in the Biotechnology industry.

( Industry Median: 17.53 vs. NAS:CYTO: -0.87 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2021-10-28), Altamira Therapeutics's stock price is $1.70. Altamira Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $. Therefore, Altamira Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Altamira Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Altamira Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.58 -1.03 -1.20 -0.77 -1.96

Altamira Therapeutics Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.77 - -1.96 -

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Altamira Therapeutics EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's EV-to-EBITDA falls into.



Altamira Therapeutics EV-to-EBITDA Calculation

Altamira Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=11.433/-9.0792435839712
=-1.26

Altamira Therapeutics's current Enterprise Value is $11.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was $-9.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altamira Therapeutics  (NAS:CYTO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Altamira Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.70/-1.473
=At Loss

Altamira Therapeutics's share price for today is $1.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Altamira Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics Business Description

Altamira Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
8 The Green, Suite 12455, Dover, DE, USA, 19901
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)